OTC · CSLLY
Healthcare · Biotechnology
$32.21
Up+$0.69 (+2.17%)
Updated Oct 12, 2026, 5:09 AM
SID Score
6.3/10
Composite research score
Smart Money
46/100
Neutral
Price performance · CSLLY
1M range · 0 trading sessions · Daily adjusted prices
CSLLY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning CSLLY.
Company
Market Activity
Research & News
CSLLY research
Company profile and research snapshot.
CSL LTD SP/ADR
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 22, 2026 | BELL POTTER SECURITIES | Hold | — |
| Sep 7, 2026 | CANACCORD GENUITY | Hold | — |
| Sep 2, 2026 | JEFFERIES | Hold | — |
| Aug 19, 2026 | MACQUARIE RESEARCH | Neutral | — |
| Jul 2, 2026 | BELL POTTER SECURITIES | Hold | — |
No generated briefing is available yet.
Yahoo · Oct 8, 2026
Investing.com -- Haemonetics Corporation (NYSE:HAE) shares jumped over 17% in premarket trading Thursday following an update on its supply agreement with CSL Plasma Inc.
Yahoo · Oct 6, 2026
HRMY vs. CSLLY: Which Stock Is the Better Value Option?
Yahoo · Oct 6, 2026
CSL (ASX:CSL) has put kidney and liver disease firmly in focus, committing an upfront US$355 million to partner with Alentis Therapeutics on lixudebart and agreeing to fund upcoming Phase 2 and 3 trials. CSL’s move on lixudebart lands after a sharp shift in sentiment, with the 90-day share price return of 43.75% contrasting with a 1-year total shareholder return that declined 10.72%. This signals short term momentum building against a weaker multi year record. Scan other kidney and liver...
Yahoo · Oct 5, 2026
Investing.com-- CSL Ltd (ASX:CSL) shares rose on Monday after the Australian healthcare company said it had agreed to pay up to $1.6 billion to jointly develop and commercialise an experimental treatment for rare kidney and liver diseases.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CSLLY.
